New class of collagen-targeted contrast agents for Magnetic Resonance Imaging
用于磁共振成像的新型胶原蛋白靶向造影剂
基本信息
- 批准号:10258404
- 负责人:
- 金额:$ 28.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAlcohol abuseAlkanesulfonatesAlkynesAnimal ModelAzidesBindingBiopsyBlood VesselsChelating AgentsChronic HepatitisClinical ResearchCollagenCollagen Type IContrast MediaCouplingDetectionDiagnosisDiseaseDopamineDoseEpidemicFibrosisFiltrationFunctional disorderGadoliniumGoalsHemorrhageHumanIn VitroInfectionInflammationInterobserver VariabilityIntravenousKidneyLeadLeftLibrariesLiverLiver CirrhosisLiver FailureLiver FibrosisMRI ScansMagnetic Resonance ImagingMalignant neoplasm of liverMedicalMetabolicMethodsMonitorMorbidity - disease rateOralOutcomeOutputPatientsPeptidesPhasePlasmaPlayPrimary carcinoma of the liver cellsReactionRegimenRiskRunningSamplingSerumSignal TransductionSmall Business Innovation Research GrantSpecificityStagingTechniquesTechnologyTimeUnhealthy DietViral hepatitisWateraccurate diagnosisbasebiomarker panelchronic liver diseaseclinical practicecostcost effectivedetection sensitivityeffective therapyelastographyimaging probeiron oxide nanoparticlelead candidatemortalitymouse modelnanoparticlenonalcoholic steatohepatitisnovelstandard of caresuperparamagnetismtooltreatment response
项目摘要
Project Summary
Chronic liver disease is one of the leading and most rapidly rising causes of mortality worldwide. Chronic liver
disease is multifactorial and can be brought upon from damages ranging from viral hepatitis infection to alcohol
abuse to poor diet. Leading these is the epidemic of nonalcoholic steatohepatitis (NASH), but all chronic liver
diseases progress to liver fibrosis if unchecked. Fibrosis may resolve following effective treatment, but when left
untreated liver fibrosis can progress to liver failure or liver cancer. Accurate diagnosis, staging, and surveillance
of liver fibrosis is key to chronic liver disease patient management. The present standard of care for diagnosis
and staging of liver fibrosis is biopsy, which runs the risk of internal bleeding, samples only a small portion of
liver, and suffers from interobserver variability.
Fibrosis stage, and not steatosis nor inflammation, is the only feature of disease associated with worse
outcomes in NASH. Besides biopsy we lack good tools to noninvasively detect liver fibrosis, stage fibrosis, or
monitor response to treatment. Elastography methods are not sensitive to early changes in disease. Serum
biomarkers and biomarker panels to identify NASH and/or liver fibrosis, are also limited and lack accuracy for
staging. None of these techniques has the accuracy to monitor treatment. An accurate, safe method to diagnose
and monitor NASH and associated fibrosis is of utmost importance in both clinical practice and clinical research.
Collagen Medical has developed type I collagen-binding peptides (CBP) conjugated to gadolinium chelates
for noninvasive MRI staging of liver fibrosis. These probes (EP-3533 and CM-101) are injected intravenously,
binding to fibrotic liver in proportion to the degree of fibrosis, while the unbound probe is rapidly renally eliminated.
Despite efficacy in multiple animal models at low doses of probe (5 – 10 µmol/kg), the anticipated cost of goods
at this dose is expected to be too high to be commercially viable.
This Phase I SBIR proposal seeks to reduce the cost of goods of a collagen-targeted MR imaging probe by
combining Collagen Medical’s CBP technology with exceedingly small iron-oxide nanoparticle (ESPION)
technology developed at MIT. ESPIONs provide strong positive contrast in T1-weighted MRI scans, are small
enough to extravasate from blood vessels, and are eliminated via renal filtration. The relaxivity of ESPIONs is 5
– 20 times higher than CM-101. A higher relaxivity should equate to a lower dose and we hypothesize that an
ESPION-CBP conjugate would be as effective at a 5 – 20 fold lower dose than CM-101, and thus a significantly
lower cost of goods. Furthermore, ESPIONs can are prepared from cheap raw materials whereas synthesis of
the bifunctional Gd-chelates that have been previously conjugated to the CBP require multiple synthetic steps
and costly chromatographic purification. Our approach is to synthesize a small library of ESPION-CBP
conjugates and screen for relaxivity, collagen-binding affinity, collagen specificity, and metabolic stability in vitro.
We will then demonstrate that our lead ESPION-CBP conjugate is capable of visualizing liver fibrosis with
superior detection sensitivity to the previously studied Gd-based collagen-targeting probe CM-101 in a murine
model of liver fibrosis.
项目摘要
慢性肝病是世界范围内死亡率上升最快的主要原因之一。慢性肝
疾病是多因素的,可以从病毒性肝炎感染到酒精的损害引起
滥用不良饮食。非酒精性脂肪性肝炎(NASH)的流行是其中的主要原因,但所有慢性肝病患者都是NASH患者。
如果不加以控制,疾病会发展为肝纤维化。纤维化可能会解决后,有效的治疗,但当左
未经治疗的肝纤维化可发展为肝衰竭或肝癌。准确的诊断、分期和监测
肝纤维化是慢性肝病患者管理的关键。目前的诊断护理标准
肝纤维化的分期是活组织检查,这有内出血的风险,只采集一小部分肝纤维化的样本。
肝脏,并患有观察者间变异性。
纤维化阶段,而不是脂肪变性或炎症,是疾病恶化的唯一特征。
NASH的结果。除了活检,我们缺乏良好的工具来无创检测肝纤维化,分期纤维化,或
监测对治疗的反应。弹性成像方法对疾病的早期变化不敏感。血清
用于鉴定NASH和/或肝纤维化的生物标志物和生物标志物组也是有限的,并且缺乏针对NASH和/或肝纤维化的准确性。
分期付款这些技术都不具有监测治疗的准确性。一种准确、安全的诊断方法
并且监测NASH和相关的纤维化在临床实践和临床研究中都是极其重要的。
Collagen Medical开发了与钆螯合物结合的I型胶原蛋白结合肽(CBP)
用于肝纤维化的非侵入性MRI分期。静脉注射这些探针(EP-3533和CM-101),
与纤维化程度成比例地结合到纤维化肝脏,而未结合的探针被快速地肾清除。
尽管低剂量探针(5 - 10 µmol/kg)在多个动物模型中有效,但预期的商品成本
预期该剂量太高而不能商业化。
该I期SBIR提案旨在通过以下方式降低胶原靶向MR成像探头的商品成本:
将Collagen Medical的CBP技术与极小氧化铁纳米颗粒(ESPION)相结合
MIT开发的技术。ESPION在T1加权MRI扫描中提供强阳性对比,体积小
足以从血管外渗,并通过肾过滤排出。ESPION的弛豫率为5
- 比CM-101高20倍。较高的弛豫率应等同于较低的剂量,我们假设,
ESPION-CBP缀合物在比CM-101低5 - 20倍的剂量下将是有效的,并且因此显著降低了剂量。
降低商品成本。此外,ESPION可以由廉价的原材料制备,而
先前已经与CBP缀合的双官能Gd螯合物需要多个合成步骤
和昂贵的色谱纯化。我们的方法是合成一个小的ESPION-CBP文库
结合物,并筛选松弛性、胶原结合亲和力、胶原特异性和体外代谢稳定性。
然后,我们将证明我们的领先ESPION-CBP结合物能够可视化肝纤维化,
在小鼠中,对先前研究的基于Gd的胶原靶向探针CM-101的上级检测灵敏度
肝纤维化模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Valerie Humblet其他文献
Valerie Humblet的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Valerie Humblet', 18)}}的其他基金
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
胰腺癌促纤维增生反应的分子 MR 成像
- 批准号:
9329960 - 财政年份:2016
- 资助金额:
$ 28.71万 - 项目类别:
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
胰腺癌促纤维增生反应的分子 MR 成像
- 批准号:
9350264 - 财政年份:2016
- 资助金额:
$ 28.71万 - 项目类别:
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
胰腺癌促纤维增生反应的分子 MR 成像
- 批准号:
9047520 - 财政年份:2015
- 资助金额:
$ 28.71万 - 项目类别:
相似海外基金
A novel animal model to study the association between alcohol abuse during late adolescence with common conditions observed in combat Veterans
一种新的动物模型,用于研究青春期后期酗酒与退伍军人中观察到的常见状况之间的关联
- 批准号:
10644999 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Reinforcement as a Prospective Predictor of Real-time Alcohol Abuse Following Bariatric Surgery
强化作为减肥手术后实时酒精滥用的前瞻性预测因子
- 批准号:
10370120 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
A novel animal model to study the association between alcohol abuse during late adolescence with common conditions observed in combat Veterans
一种新的动物模型,用于研究青春期后期酗酒与退伍军人中观察到的常见状况之间的关联
- 批准号:
10368295 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Reinforcement as a Prospective Predictor of Real-time Alcohol Abuse Following Bariatric Surgery
强化作为减肥手术后实时酒精滥用的前瞻性预测因子
- 批准号:
10705563 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
The Functional Implications of Astrocytic GPCR-signaling on Alcohol Abuse
星形胶质细胞 GPCR 信号传导对酒精滥用的功能影响
- 批准号:
10472456 - 财政年份:2021
- 资助金额:
$ 28.71万 - 项目类别:
Trauma and Neurobiological Threat Reactivity as Risk Factors for Alcohol Abuse in Youth
创伤和神经生物学威胁反应作为青少年酗酒的危险因素
- 批准号:
10582520 - 财政年份:2021
- 资助金额:
$ 28.71万 - 项目类别:
Trauma and Neurobiological Threat Reactivity as Risk Factors for Alcohol Abuse in Youth
创伤和神经生物学威胁反应作为青少年酗酒的危险因素
- 批准号:
10368089 - 财政年份:2021
- 资助金额:
$ 28.71万 - 项目类别:
The Functional Implications of Astrocytic GPCR-signaling on Alcohol Abuse
星形胶质细胞 GPCR 信号传导对酒精滥用的功能影响
- 批准号:
10089613 - 财政年份:2021
- 资助金额:
$ 28.71万 - 项目类别: